Brain elimination half-life of fluvoxamine measured by 19F magnetic resonance spectroscopy

American Journal of Psychiatry

Volumn 155, Issue 3, 1998, Pages 380-384

  Strauss, Wayne L ^a   Layton, Matthew E ^a   Dager, Stephen R ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORINE; FLUVOXAMINE;

ADULT; ANORGASMIA; ARTICLE; CLINICAL ARTICLE; DRUG BRAIN LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG WITHDRAWAL; ENZYME KINETICS; FEMALE; HUMAN; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; SEXUAL DYSFUNCTION; WITHDRAWAL SYNDROME;

EID: 0031941954     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.155.3.380     Document Type: Article

References (19)

1. Dager SR, Steen RG: Application of magnetic resonance spectroscopy to the investigation of neuropsychiatric disorders. Neuropsychopharmacology 1992; 6:249-266
2. 19F MR spectroscopy. J Neural Transm Gen Sect 1995; 99:1-6
3. 19F magnetic resonance spectroscopy investigation in vivo of acute and steady-state bruin fluvoxamine levels in obsessive-compulsive disorder. Am J Psychiatry 1997; 154:516-522
4. Finley PR: Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions. Ann Pharmacother 1994; 28:1359-1369
5. Palmer KJ, Benfield P: Fluvoxamine: an overview of its pharmacological properties and review of its therapeutic potential in non-depressive disorders. CNS Drugs 1994; 1:57-87
6. Wilde MI, Plosker GL, Benfield P: Fluvoxamine: an updated review of its pharmacology, and therapeutic use in depressive illness. Drugs 1993; 46:895-924
7. Rowland M, Tozer TN: Clinical Pharmacokinetics: Concepts and Applications. Baltimore, Williams & Wilkins, 1995
8. de Vries MH, Raghoebar M, van Harten J: Single and multiple oral dose fluvoxamine kinetics in young and elderly subjects. Ther Drug Monit 1992; 14:493-498
9. Dorevitch A, Davis H: Fluvoxamine-associated sexual dysfunction. Ann Pharmacother 1994; 28:872-874
10. Kline MD: Fluoxetine and anorgasmia (letter). Am J Psychiatry 1989; 146:804-805
11. Sovner R: Anorgasmia associated with imipramine but not desipramine: case report. J Clin Psychiatry 1983; 44:345-346
12. Rothschild AJ: Selective serotonin reuptake inhibitor-induced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry 1995; 152:1514-1516
13. Karson CN, Newton JE, Livingston R, Jolly JB, Cooper TB, Sprigg J, Komoroski RA: Human brain fluoxetine concentrations. J Neuropsychiatry Clin Neurosci 1993; 5:322-329
14. Lazowick AL, Levin GM: Potential withdrawal syndrome associated with SSRI discontinuation. Ann Pharmacother 1995; 29:1284-1285
15. Szabadi E: Fluvoxamine withdrawal syndrome (letter). Br J Psychiatry 1992; 160:283-284
16. Black DW, Wesner R, Gabel J: The abrupt discontinuation of fluvoxamine in patients with panic disorder. J Clin Psychiatry 1993; 54:146-149
17. Overmars H, Scherpenisse PM, Post LC: Fluvoxamine maleate: metabolism in man. Eur J Drug Metab Pharmacokinet 1983; 8:269-280
18. 19F MRS spin relaxation and localized spectroscopy of fluoxetine in human brain. Magn Reson Med 1994; 31:204-211
19. 19F NMR spectroscopy. Magn Reson Med (in press)